CDTI PERTE Salud Vanguardia
Funds CDTI PERTE Salud Vanguardia for Spain to support precision care, health data, oncology, and regenerative technology research.
CDTI PERTE Salud Vanguardia sits under CDTI E.P.E. Centro para el Desarrollo Tecnológico y la Innovación, Spain's public technology agency. The programme is the CDTI-led arm of the PERTE Salud Vanguardia agenda, built around precision medicine, data-driven health, oncology, rare diseases, and regenerative medicine. It is a national route, not a general-purpose fund, and it is aimed at health technology development that can be carried by companies operating in Spain. The instrument is a grant. Awards run from EUR 47,000 to EUR 2.82 million on an annual cycle, with Spanish registration and operations required and consortium delivery required. The route is company-led rather than individual-led, and the health technology scope points to projects that can combine research, development, and industrial execution. Its value lies in scale and coordination. Applicants that can assemble a credible consortium and connect the technical work to a national health priority will fit best, because the programme is built for collaborative delivery rather than one-off prototype support. For companies active in medtech, diagnostics, digital health, or advanced therapeutics, it is one of CDTI's clearest public channels into Spain's health innovation agenda.
No upcoming rounds verified. Cadence: Annual.